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Abstract
Background: In the absence of a French health-related quality of life (QOL) instrument for renal
transplant recipients (RTR), we developed a self-administered questionnaire: the ReTransQol
(RTQ).
Methods: This questionnaire was developed using classical methodology in the following three
phases over a two-year period: Item Generation phase, identifying all possible items having adverse
impact on the QOL of RTR, Item Reduction phase, selecting the most pertinent items related to
QOL, and Validation phase, analyzing the psychometric properties. All RTR involved in these
phases were over 18 and were randomly selected from a transplant registry.
Results: Item generation was conducted through 24 interviews of RTR. The first version of RTQ
(85 items) was sent to 225 randomized RTR, and 40 items were eliminated at the end of the item
reduction phase. The second version of RTQ (45 items) was validated from 130 RTR, resulting in
the RTQ final version. The factor analysis identified a structure of five factors: Physical Health (PH),
Mental Health (MH), Medical Care (MC), Fear of losing the Graft (FG) and Treatment (TR). The
psychometric properties of RTQ were satisfactory. Comparison between known groups from the
literature confirmed the construct validity: patients without employment or living alone have lower
QOL scores, and women have lower QOL scores than men. RTQ was more responsive than SF36
to detect changes in the QOL of RTR who were hospitalized secondary to their renal disease in
the 4 weeks preceding their inclusion.
Conclusion: According to French public health priorities, RTQ appears to be a reliable and valid
questionnaire.
Introduction
Health-Related Quality of Life (QOL) measurements have
become an important outcome measure in addition to
morbidity and mortality rates, both in population health
assessment and in clinical trials [1,2]. QOL indicators are
based on the completion of standardized and well-vali-
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dated questionnaires, addressing the impact of health sta-
tus in individuals, as perceived by themselves through
physical, emotional, mental, social and behavioral com-
ponents [3]. Formal Quality of Life (QOL) analyses have
defined the patient's role as essential to the transplant
process, providing health care professionals with informa-
tion regarding the psychosocial and physical impact of
kidney transplantation [4,5].
Kidney transplantation is the therapy of choice for end-
stage renal failure when focusing on survival transplanta-
tion [6-9] and also provides the greatest QOL, whose
measurement has become an important outcome param-
eter [10-16].
Few specific questionnaires of QOL have been developed
[17-19] for Renal Transplant Recipients (RTR), but they
were not validated or available in French. Among ques-
tionnaires adapted to the general population, SF36
remains the most widely used in studies of QOL [10,20-
27]. We purposefully did not make a direct transcultural
validation of one of the existent questionnaires for RTR
because some dimensions were lacking in these question-
naires, such as those related to medical care. Additionally,
specific questionnaires, particularly the ESRS-CL [18]
were, in our opinion, too centered on symptomatology
and drug side effects. Lastly, existing questionnaires
require face-to-face administration, when on the contrary
we purposefully wished to develop a self-administered
questionnaire, an important approach of this study.
This paper describes the development and validation of
this questionnaire: The ReTransQol (RTQ).
Methods
Study Design for the scale development included three
phases over a two-year period:
Phase 1: item generation, identifying all possible items
having adverse impact on the QOL of RTR,
Phase 2: item reduction, selecting the most pertinent items
related to QOL,
Phase 3: validation of the psychometric properties of RTQ.
Patients
For each phase, RTR aged over 18 and having received
their graft at least 6 months prior were included. RTR who
were non-French speaking, unable to answer or lost to fol-
low-up were excluded.
For each phase, RTR were randomly selected from the reg-
istry of the transplant center of Marseille, avoiding those
included in previous phases. The study was approved by
the local medical ethics committee. All patients gave
informed consent to participate.
The procedure for data collection
For each phase, the procedure of data collection varied:
For the item generation phase, face-to-face interviews were
recorded and transcribed, collecting individual views on
health perception, which identified dimensions of QOL
that were most affected by renal transplantation. An inter-
view guide was based upon a structured literature review
[10]. Interviews of new patients ended when data satura-
tion had been achieved.
For item reduction, questionnaires were sent to the
patient's residence; non-respondents were followed-up by
a second letter three weeks later, then by phone if no
response. Three questionnaires were involved: RTQ V1
(first version), socio-demographic questionnaire and a
clinical questionnaire, based on medical records and com-
pleted by nephrologists.
For the validation phase, the procedure was identical to the
precedent phase, but was done twice, at the start period
(M0), and 6 months later (M6); additional questionnaires
were utilized (SF36 and a validated stressful life events
scale).
Data collection instruments
Except the RTQ, which is this study's specifically-devel-
oped instrument, the following instruments were used:
SF36 is a generic QOL scale consisting of 36 items describ-
ing eight dimensions: Physical Function (PF), Social Func-
tion (SF), Role Function – Physical (RFP), Role Function
– Emotional (RFE), Emotional Well-being (EW), Vitality
(VT), Bodily Pain (BP) and General Health Perception
(GHP). Each dimension ranges from 0 to 100; the higher
the score, the better the perceived state of health [28].
A validated stressful life events scale is a checklist of stress-
ful life events occurring in a given time period (for the
present study, period M0–M6). To complete the checklist,
patients quoted the events that occurred during the
period, assigning to each item a level from 0 (no stress
impact) to 4 (maximal impact) [29].
Socio-demographicquestionnaires  included items on age,
sex, living arrangement, employment status, and familial
status.
Clinical questionnaire included etiology of end-stage renal
failure, hospital admissions in the past year, comorbidi-
ties, treatments, type of previous Renal Replacement Ther-
apy (RRT) (hemodialysis or peritoneal dialysis), length ofHealth and Quality of Life Outcomes 2008, 6:78 http://www.hqlo.com/content/6/1/78
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time on RRT, any rejection episodes, time elapsed since
transplantation, and any previous unsuccessful kidney
transplantation. Some questions were added to the ques-
tionnaire for the last phase of validation.
Statistical methods
Item generation
Each transcript was examined independently by two
researchers. Data derived from verbatim transcription and
field notes were initially summarized and analyzed. Tex-
tual data were reduced to concepts through open coding
and logical groups of concepts were clustered into catego-
ries, and then reorganized into a pool of items. These
items were discussed by a combined group of experts and
patients to test their comprehensiveness and acceptability,
and later encoded.
Item reduction
This phase selected the most clinically relevant items, rel-
ative to response rate, inter-item correlation, and floor or
ceiling effects. The items were eliminated in cases of miss-
ing values exceeding 5%, high inter-item correlation (r >
0.70), or floor or ceiling effects, homoegeneously
answered on response levels (over 70% for one response
level). Moreover, a first factor analysis established which
of the provisional RTQ items belonged to dimensions and
should be retained. Items which loaded < 0.40 for all the
factors were deleted. Questions were weighted equally,
and the individual's score for each of the 5 dimensions
was obtained by computing each item's mean score
within every dimension. A missing scale score was substi-
tuted if over half of the items in each scale were missing.
All dimensions were linearly transformed to a 0–100
scale, with 100 indicating the most favorable QOL.
Validation
Validation of the RTQ was undertaken through the fol-
lowing phases:
Item level analysis
Feasibility was measured by using the percentage of miss-
ing values for each item and item-response distribution.
Item-internal consistency was assessed by correlating each
item with its dimension (using the recommended stand-
ard for correlation ≥ 0.40 [30,31]). Item-discriminant
validity was assessed by determining the extent to which
items correlate more highly with dimensions they are
hypothesized to represent than with different dimensions.
Internal consistency reliability of Scale scores
Cronbach's alpha coefficients were computed to estimate
the internal consistency reliability of each dimension
score. A reliability of at least 0.70 is recommended to
compare groups of patients [32,33].
Construct validity
Construct validity was examined by factor analysis with
varimax rotation, which tested the underlying dimensions
of the 45-item RTQ. Correlation of RTQ scales with the
score of SF36's same dimensions was studied.
Known group validity explores the questionnaire's ability
to show differences between patient groups with different
health status and/or characteristics. We used variables
identified in the literature: age, sex, employment status,
familial status, BMI, treatment, comorbidities, hospitali-
zation, and previously failed transplant [25,34,35]. We
specify results quantified only for RTQ and indicate the
differences found with SF36.
Content validity
Patients were requested to point out important domains
of their life that were not mentioned in the RTQ by a final
open-ended question. Their responses and comments
were analyzed. Cognitive debriefing was performed with a
subsample of 10 patients.
Reproducibility and sensitivity to change
The analyses of reproducibility and sensitivity to change
were performed on patient data between the time periods
M0 and M6. These patients were categorized retrospec-
tively related to data on changes in health status and
stressful life events during the period of follow-up. Physi-
cians encoded changes in health status in three modali-
ties: stabilization, degradation or improvement of health
status. Patients were classified as undergoing a stressful
life event according to their responses to the "Stressful life
events scale." Two categories were formed: those with a
stressful life event (coded ≥ 3), and those without (< 3).
The test-retest reliability of RTQ was assessed for patients
whose health status was declared unchanged between M0
and M6, and for those without stressful events. Intraclass
Correlation Coefficients (ICC) were computed between
scale scores for the two assessments (≥ 0.70 considered
satisfactory) [36]. Sensitivity to change was assessed for
patients with a degradation or improvement of their
health status and/or for those who had a stressful event
between the two time periods. RTQ scores were compared
using the paired t-test.
Figure 1 summarizes the different phases of development
of RTQ.
Results
Item generation phase
An initial pool of 102 questions was generated by content
analysis of 24 recorded interviews conducted with RTR;
the QOL domains most commonly affected by renal
transplant were identified. The set of 102 items was dis-Health and Quality of Life Outcomes 2008, 6:78 http://www.hqlo.com/content/6/1/78
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cussed by a pluridisciplinary group (nephrologists, inter-
viewers, methodologists and patients belonging to the
national association of end stage renal disease patients) to
test their comprehensiveness and acceptability, prompt-
ing the rejection of 17 items. This group encoded the first
version of RTQ, comprised of the provisional 85 items on
a five to six-point ordinal scale, according to two reference
time periods : during the previous 4 weeks, or since trans-
plantation.
Item reduction phase
A sample of 225 RTR was recruited for this phase, and 186
responded (response rate 82.6%). The respondents' socio-
demographic and medical characteristics are presented in
tables 1 and 2. Items were eliminated due to missing val-
ues (n = 23), floor or ceiling effects (n = 5), low factor
loading on initial factor analysis (n = 3), or a high inter-
correlation coefficient (n = 9). Finally, 40 items were
The different phases of development of ReTransQol Figure 1
The different phases of development of ReTransQol
                                                                                     M RÉDUCTION   Data collection  
Literature review 
Face-to-face interviews  
Pool of 102 items 
Group of experts and patients tested 
comprehensiveness and acceptability 
Data collection
ReTransQol V1 
Sociodemographic questionnaire 
Clinical questionnaire  
Data collection during two periods: M0 and M6
ReTransQol V2  
SF36  
Sociodemographic questionnaire 
Clinical questionnaire  
Events stressful  
ReTransQol Version 1 (V1): 85 items 
PHASE OF DEVELOPMENT 
ReTransQol Version 2 (V2): 45 items 
ITEM REDUCTION 
VALIDATION 
Subsample 
24 RTR 
Subsample 
225 RTR 
Subsample 
130 RTR 
ReTransQol Final Version Health and Quality of Life Outcomes 2008, 6:78 http://www.hqlo.com/content/6/1/78
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rejected during this phase. Items and responses modalities
are presented in Table 7.
Validation phase
A sample of 130 RTR, different from those involved in the
item reduction phase, was randomly chosen for the vali-
dation step study; 104 patients were included (response
rate 80%, Tables 1 and 2).
Item level analysis and internal consistency reliability scores
In accordance with the results of item selection, all
response levels of each item were homoegeneously
answered. At the item level, missing data did not exceed
5%. The acceptability of RTQ was satisfactory (77% com-
pletion). Table 3 presents results of internal item consist-
encies.
Construct validity
- Factor analysis
The factor analysis with varimax rotation identified a
structure of five factors, which accounts for 46.3% of the
total variance (Table 4). The content of each dimension
was entitled the following: Physical Health (PH, ten
items), Medical Care (MC, eleven items), Fear of losing
the Graft (FG, six items), Treatment (TR, nine items) and
Mental Health (MH, nine items).
- Correlation between SF36 and RTQ
Positive correlations were found between RTQ scores and
SF36 scores. The dimension scores of RTQ had medium to
high correlation (> 0.6) with those of SF36 assessing sim-
ilar dimensions: PH-RTQ with PF-SF36, RFP-SF36, VT-
SF36, and MH-RTQ with EW-SF36. The other RTQ dimen-
sion scores: MC-RTQ, FG-RTQ and TR-RTQ were not
highly correlated with SF36 (Table 5).
- Known Group Validity
Table 6 presents a summary of variables associated with a
decreased or increased QOL.
Patients living alone reported significantly lower scores on
the dimension MH (63.2 ± 2.2 vs. 71.4 ± 14.9, p < 0.05).
Patients without employment reported lower scores on
dimension PH (53.3 ± 19 vs. 65.6 ± 16.9, p < 0.05) and
MH (65.8 ± 17.7 vs. 74.3 ± 15.4, p < 0.05), and for all
dimensions of SF36 except EW. Women reported lower
scores on dimension TR (62.90 ± 14.7 vs. 67.9 ± 15.6, p <
0.05). Measures of RTQ were not influenced by age, yet
patients over 55 reported significantly lower scores for
SF36 on dimensions PF, SF, RFP, RFE and BP.
The RTR hospitalized during the previous 12 months
reported significantly lower scores on dimension PH for
RTQ (51.9 ± 18.8 vs. 63.9 ± 17.9, p < 0.01) and for SF36
on dimension PF, RFP, RFE and GHP. However, patients
hospitalized for transplant complications reported signif-
icantly lower scores, for RTQ only on the dimensions PH
(51.8 ± 18.8 vs. 69.96 ± 10.2, p < 0.01) and MC (60.7 ±
12.2 vs. 65.9 ± 10.2, p < 0.01), and not for SF36. The
period of time since transplantation was significantly cor-
related with the score of RTQ on the TR dimension (r =
0.22, p < 0.01) and score of SF36 on the BP dimension.
RTR with a previous unsuccessful kidney transplant
reported higher scores for RTQ on dimension FG (66.7 ±
16.7 vs. 52.4 ± 20.9, p < 0.05) and dimension TR (79 ± 6.6
Table 1: Test Sample Characteristics
Item reduction Validation phase
Socio-demographic data
Sex, % males 62.4 63.5
Age, years, mean ± SD 50.7 ± 14.6 49.4 ± 12.8
(range) (19 – 81) (20 – 71)
Living arrangement :
Live alone, % 18.6 20.2
Children, % 65.9 75.5
Patients conceived child after transplantation, % 6.5 9.7
Employment status
Employed, % 28.5 37.5
Unemployed :
Declared in chronic ill heath (health pension), % 37.4 36.4
Retired, % 40.5 49.1
Others, % 22.1 14.5
Return to occupation after transplantation, % 37.2 51.1Health and Quality of Life Outcomes 2008, 6:78 http://www.hqlo.com/content/6/1/78
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vs. 64.3 ± 15.5, p < 0.01), and for SF36 on dimensions VT
and GHP. Measures of RTQ and SF36 were neither influ-
enced by the kind of dialysis, nor the duration of dialysis,
nor a possible rejection episode.
Considering RTQ-specific results, Body Mass Index
showed a significant negative correlation with RTQ score
on the dimension PH (r = -0.258, p < 0.05), and smokers
reported lower scores on the dimension PH (51.5 ± 19.7
vs. 63.1 ± 19.5, p < 0.01). Patients with Diabetes Mellitus
reported significantly lower RTQ scores on dimension MC
(38.4 ± 21.2, p < 0.05) and FG (38.4 ± 21.2 vs. 58.9 ±
19.7, p < 0.01). No difference was found for the SF36 in
all of these characteristics.
Patients with a stressful life event reported lower scores on
RTQ for the dimension PH (56.4 ± 20.3 vs. 68.8 ± 17.2, p
< 0.01) and MH (65 ± 10 vs. 74.2 ± 16.7, p < 0.021), and
lower scores for SF36 for the dimensions SF, EW, and VT.
Content validity
A cognitive debriefing was performed with a group of 15
RTR, members of the national association of End-Stage
Renal Disease patients. The group confirmed the perti-
nence of the five dimensions, and the relevance of the
items. The dimension of "Medical Care," which is not
evoked in other QOL RTR-specific questionnaires, seems
to be of high importance in relation to the patients' QOL.
Table 2: Medical Data
Item reduction Validation phase
Period of transplantation, years 6.8 ± 3.7 5.4 ± 3.14
Previous unsuccessful kidney transplants, % - 9.6
Patient with rejection 23.2 21.4 %
Cause of ESRD
Chronic glomerular nephritis, % 42 40.4
Diabetic nephropathy, % 3 2.9
Vascular nephropathy, % 4.5 3.8
Interstitial nephropathy, % 13.5 10.6
Hereditary nephropathy,% 17 23.1
Unclassified nephropathy,% 20 19.2
Different modalities of dialysis
Hemodialysis 97.3 96.2
Peritoneal dialysis 2.7 3.8
Duration of dialysis, years, mean ± SD 2.5 ± 2 3.8 ± 4.2
Comorbidities
Hypertension 78.8 88.5
Diabetes 13 13.5
Hepatitis 0.6 6.7
Peripheral vascular disease 0.6 5.8
Depression -3 . 8
Smoking status 36.5 31.1
BMI, kg/m2, mean ± SD 25.5 ± 4.7 24.5 ± 4.0
Comorbidity index, mean ± SD 1.6 ± 0.9 1.5 ± 0.8
Treatments
Calcineurin inhibitors 94.6 96.2
Corticosteroids 89.3 97.1
Antimetabolites 75.3 77.9
Antihypertensive drugs 87.1 90.4
Antilipemic agents 53.2 45.2
Antidiabetic agents 9.7 15.4
Antithrombotics 28.5 29.8
Protease Inhibitors 19.9 26.0
Erythropoietin therapy 12.2 10.6
Hospital admissions
During the last 12 months - 45.2
Related to Kidney Transplantation - 66.0Health and Quality of Life Outcomes 2008, 6:78 http://www.hqlo.com/content/6/1/78
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Reproducibility and sensitivity to change
For patients estimated as clinically stable between M0 and
M6 (n = 56; 83.6%), high correlation coefficients (CC)
between scale scores for the two assessments were all sig-
nificant (p < 0.001): PH = 0.82, MH = 0.73, MC = 0.63, TR
= 0.76 and FG = 0.76.
For patients without stressful life events between M0 and
M6 (n = 29; 43.3%), high CC between scale scores for the
two assessments were significant (p < 0.001) for four
dimensions: PH = 0.80, MH = 0.70, TR = 0.79 and FG =
0.69. For the dimension MC, CC is lower (0.380) but sig-
nificant (p < 0.019).
For patients who were clinically stable and without stress-
ful life events (n = 23; 34.3%), the CC are also high and
significant between M0 and M6 (p < 0.001) for four
dimensions (PH = 0.79, MH = 0.72, TR = 0.82 and FG =
0.68), and lower for the dimension MC (0.39), but signif-
icant (p < 0.027).
Among the 67 patients followed between M0 and M6, 8
patients showed deterioration in health status, 38 patients
experienced a stressful life event and 4 patients showed
both of these characteristics. Significant differences were
neither found for the five dimensions of RTQ nor dimen-
sions of SF36 among any of these groups of patients.
Discussion
The psychometric properties of RTQ are satisfactory with
an exception for the sensitivity to change, due to the low
number of subjects with change in health status during
the period of the study. Subject acceptability was excellent
with a low percentage of missing data. The five dimen-
sions were confirmed by the results of the principal com-
ponent analysis. Some items (nine out of forty-five) had,
for their specific dimension, a factor loading under the
recommended threshold of 0.40 [30,31] and/or cross-
loading. Nevertheless, they were retained due to their clin-
ical relevance in terms of content validity. For the same
reasons, the item "stress" (Q23) remained in the MH
dimension, despite its higher loading in the PH dimen-
sion. This classification provided better results for reliabil-
ity, content validity and clinical validity.
The RTQ revealed specific dimensions of QOL in renal
transplant recipients (RTR). The dimensions "Physical
Health" (PH) and "Mental Health" (MH) of the RTQ are
similar to those of the SF36, but three other dimensions
give specificity to the questionnaire: Fear of losing the
Graft (FG), Treatment (TR) and Medical Care (MC). These
concerns are found in other questionnaires published for
RTR [17-19], but generally not individualized as specific
dimensions. For example, the fear of losing the graft is
included in the Mental Health dimension in Franke's
questionnaire, the ESRD Checklist [18], and is a specified
dimension in Laupacis' questionnaire entitled "Uncer-
tain/Fear" [19]. In the same way, items concerning treat-
ment are always present, though often limited to the side
effects of drugs. For example, Laupacis' questionnaire pre-
sented a dimension called "Appearance," which specified
the adverse effects of immunosuppressive medication like
excessive hair growth, excessive appetite, weight and acne
[19]. In Franke's questionnaire, treatment is present in
two dimensions called "side effects of corticosteroids" and
"increased growth of gums and hair," which are two spe-
cific effects of calcineurin inhibitors [18]. Conversely to
these questionnaires, RTQ proposes a dimension of treat-
ment which is more holistic. We think that questionnaires
which list side effects, many of which are not specified,
could possibly become obsolete as treatments evolve.
Instead, we included items about the embarrassment
caused by the side effects of drugs, and questions about
the difficulties of compliance. Finally, the patient's rela-
tionship with both the doctor and the medical team
("Medical Care" of RTQ) is not dealt with by other vali-
Table 3: Internal Consistencies
ReTransQOL
Dimensions
Mean ± SD
(Min – Max)
Cronbach's α
coefficient
(range if item was deleted)
IICa
(Min – Max)
IIC
% > 0.40
IDVb IDV
% < 0.40
Physical Health
(PH)
58.5 ± 19.2
(13.9 – 95.3)
0.86
(0.84 – 0.86)
0.48 – 0.73 100% 0.07 – 0.50 92.5%
Mental Health
(MH)
69.3 ± 17.3
(4.9 – 100)
0.84
(0.80 – 0.85)
0.38 – 0.71 88.9% 0.04 – 0.48 83.3%
Medical Care
(MC)
64.4 ± 11.0
(37.3 – 84.8)
0.83
(0.79 – 0.83)
0.44–0.70 100% 0.01 – 0.44 97.7%
Fear of losing the graft (FG) 53.8 ± 20.9
(3.6 – 96.4)
0.79
(0.75 – 0.78)
0.64 – 0.78 100% 0.07 – 0.53 95.8%
Treatment (TR) 65.8 ± 15.5
(23.1 – 94.8)
0.70
(0.66 – 0.71)
0.37 – 0.66 77% 0.01 – 0.49 91.6%
a ICC, Internal Item Consistency correlation coefficient: Range of correlations between items and their dimension
b IDV, Item Discriminant Validity : Range of correlations between items and other dimensionHealth and Quality of Life Outcomes 2008, 6:78 http://www.hqlo.com/content/6/1/78
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Table 4: Dimension and factor loadings identified using principal component analysis and the orthogonal varimax rotation (only factor 
loading >0.3 are mentioned)
Factors
Dimensions Labels 1 2 3 4 5 Item number
Eigenvalues 9.25 4.10 2.99 2.43 2.08
% of variance 20.56 9.12 6.65 5.4 4.6
Physical Health- PH .726 q5
.674 q6
.641 q36
.588 .355 q7
.573 q8
.551 q4
.538 .313 q14
.536 q9
.508 q33
.305 q35
Medical Care – MC .767 q43
.737 q42
.708 q40
.645 q41
.633 q49
.608 q45
.574 q44
.544 q46
.327 .370 q34
.474 .330 q13
.387 .307 q17
Fear of losing graft – FG .719 q31
.709 q32
.689 q16
.668 q30
.622 q15
.561 .338 q29
Treatment – TR .327 .305 q39
.389 .617 q1
.569 q11
.565 q12
.536 .547 q3
.356 .546 q38
.524 q10
.394 q2
.304 .379 q37
Mental Health – MH .671 q28
.657 q19
.650 q21
.647 q20
.574 q22
.464 .308 .512 q23
.500 .404 q26
.478 .312 q27
.595 .432 q24Health and Quality of Life Outcomes 2008, 6:78 http://www.hqlo.com/content/6/1/78
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Table 5: Correlation between RetransQol and SF36
ReTransQol
SF36 Physical Health Mental Health Medical Care Fear of losing the Graft Treatment
Physical Function- PF 0.680** 0.445** 0.268** 0.133 0.387**
Social Function- SF 0.641** 0.605** 0.184 0.290** 0.489**
Role Function-Physical-RFP 0.554** 0.450** 0.153 0.085 0.276**
Role Function-Emotional-RFE 0.612** 0.618** 0.241** 0.190 0.389**
Emotional Well-being – EW 0.543** 0.638** 0.235** 0.385** 0.474**
Vitality- VT 0.746** 0.559** 0.230* 0.366** 0.593**
Bodily Pain- BP 0.564** 0.451** 0.113 0.163 0.546**
General Health Perception-GHP 0.760** 0.498** 0.318** 0.356** 0.497**
Physical Score Composite 0.635 ** 0.374** 0.117 0.101 0.388**
Psychological Score Composite 0.641** 0.760** 0.223 0.375** 0.546**
** p < 0.001
Table 6: Known Group Validity
ReTransQol SF36
PH MH MC FG TR PH SF RF RE MH V BP GH
Variables associated with a decreased quality of life
Unemployed + + + + + + + + +
Living alone +
Female +
Age > 55 ++++ +
Hospitalizations in previous 12 months + + + + +
Hospitalizations in previous 12 months for KT + +
Period of transplantation + +
Comorbidities index + + + +
Diabetes + +
Depression + + +
BMI +
Smoking status +
Stressful life events + + + + +
Variables associated with increased quality of life
Previous unsuccessful Kidney transplants + + + +
Antimetabolites +
+ = Indicates a statistically significant relationshipHealth and Quality of Life Outcomes 2008, 6:78 http://www.hqlo.com/content/6/1/78
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Table 7: Items and responses modalities
Item number Items label Response modalities
1 Have you had physical pain? All most time
2 Has your graft bothered you? Most of time
3H a v e  y o u  f e l t  t i r e d ? A good bit of the time
4 Do you engage in physical exercise? Some of the time
5 Do you feel energetic? A little of the time
None of time
6 You are as well as anyone else Definitely agree
7 You have stopped doing certain things. Mostly agree
8 You feel autonomous. Not agree not disagree
9 You can do your housework and errands by yourself. Mostly disagree
Definitely disagree
10 Do you feel physically affected?
11 Are you annoyed by the side effects of treatment?
12 Is your weight a problem for you?
13 Do you feel relieved?
14 Do you feel sick? No at all
15 Have you been able to forget that you received a graft? A little bit
16 Do you often think about your graft? Moderately
17 Are you satisfied with your graft? Quite a bit
18 Does your family offer you moral support? Extremely
19 Has your family accepted your illness?
20 Do you feel misunderstood by the people around you?
21 Do you feel close to your friends?
22 Do you feel sad?
23 Have you enjoyed life as much as possible?
24 Do you feel discouraged? All most time
25 Are you able to put up with daily worries and stress? Most of time
26 Do you feel isolated? A good bit of the time
27 Are you anxious about your state of health? Some of the time
28 Does waiting for the results of medical tests distress you or make you feel scared? A little of the time
29 Do you think about a possible return to dialysis? None of time
30 Do you still sometimes think about dialysis?
31 You would say that you have a normal life. Definitely agree
32 You live with the graft as if you have a second life, a rebirth. Mostly agree
33 Do you think you will have enough income to provide for your needs? Not agree not disagree
Mostly disagree
Definitely disagree
34 Do you have hobbies/leisure activities? All most time
Most of time
A good bit of the time
Some of the time
A little of the time
None of time
35 Is taking medications a constraint for you?
36 Are you scared of the possible side effects of the anti-rejection treatment?
37 Are your doctor's orders restrictive?
38 Do you trust your nephrologist?
39 Do you have trust in the prescribed treatments?
40 Are you satisfied by your nephrologist's ability to listen? No at all
41 Do you feel sufficiently informed by your nephrologist? A little bit
42 Do you feel like you are sufficiently informed about the side effects of your treatments? Moderately
43 Do you feel like you are sufficiently informed about complications of the graft? Quite a bit
44 Do you feel supported by the medical team? Extremely
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dated questionnaires, even though patients attribute
importance to medical information and health education.
Comparisons between different demographic subgroups
confirm previous empirical works showing their varia-
tions [25,34,35]. For example, results confirm that
patients without employment or living alone have lower
QOL scores. Also, women have lower QOL scores in com-
parison with men, only for the dimension of "treatment."
This is probably in relation to the impact of immunosup-
pressive treatments on the body image [18,25,34,35].
RTQ was more responsive to detect changes in QOL for
patients hospitalized for renal disease, for those with a
high BMI, or comorbidities, especially Diabetes Mellitus.
Although age was found in the literature to be a predictive
factor of QOL, no significant correlation was found
between RTQ and age. But most QOL studies focusing on
RTR have assessed QOL with generic questionnaires [10],
and among studies with QOL-specific questionnaires, its
correlation with age is not precisely discussed [17-19].
Probably age is far more a general determinant of quality
of life than it is specific to kidney transplantation. The
RTQ can be utilized alone or in complement with the
SF36, according to the clinician's objective. The interest of
using the SF36 in complement with RTQ essentially is to
be able to compare levels of QOL between RTR and other
groups of patients (from different countries, or with other
pathologies, etc.).
Conclusion
This study reported the stages of development and valida-
tion of a QOL questionnaire for RTR, developed in
response to a lack of any validated instrument for those
patients in the French language. The quality of life for
patients with chronic diseases has become a public health
priority in France, especially since the new Public Health
Law [37].
Psychometric properties allow this questionnaire to be
used for monitoring the impact of different treatments on
the renal transplant population, more effectively than pre-
viously possible. In addition, regular use of the RTQ can
complement current evaluation of "good transplantation
practice," while highlighting problem areas for specific
intervention. We envision continuing this work by the fol-
low-up of a prospective cohort to study the sensitivity to
change and the clinically significant threshold. In the
future, we plan to validate the questionnaire in English.
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